Bayer's drug sales in Asia-Pac up 8.6% in 2016
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
PHARMACEUTICAL company Bayer reported an 8.6 per cent increase to 4.8 billion euros (S$7.21 billion) in drug sales in the Asia-Pacific region in 2016.
This is its sixth consecutive year of growth - nearly doubled from 2.6 billion euros in 2010.
Claus Zieler, Bayer's senior vice-president and head of commercial operations at its Asia-Pacific pharmaceutical division, said innovation is the foundation of his company's success.
"Our portfolio of innovative medicines, which addresses the unmet medical needs of patients in the Asia-Pacific region, drives our strong business growth today," he said.
Bayer expects global sales of more than 17 billion euros for its pharmaceuticals division in 2017.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
